NMS · Biotechnology

Inhibrx Biosciences Inc. (INBX) Stock

$81.54 -0.01% NMS: INBX Healthcare

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms.

Valuation

MetricValue
Price$81.54
Market Cap$1.20B
P/E Ratio-9.72
P/B Ratio-60.42
P/S Ratio920.33
EPS (TTM)$-9.04
52-Week High$155.29
52-Week Low$20.55
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-563.89%
ROA-70.77%
ROCE-78.15%
Gross Margin-13500.00%
Operating Margin-13500.00%
Net Margin-100.14%
Debt/Equity-0.28
Current Ratio3.91

Annual Financials (USD)

Metric20212022202320242025
Revenue$7.0M$2.0M$2.0M$0$1.0M
Operating Profit$-77.0M$-129.0M$-219.0M$-331.0M$-135.0M
Net Profit$-82.0M$-145.0M$-241.0M$1.7B$-140.0M
EPS$-2.15$-3.62$-5.12$116.58$-9.04
Op Margin-1074.6%-5890.4%-12178.9%-165724.0%-10386.5%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$150.0M$291.0M$308.0M$181.0M$146.0M
Total Liabilities$98.0M$233.0M$264.0M$47.0M$138.0M
Cash$131.0M$274.0M$278.0M$153.0M$124.0M
Borrowings$72.0M$207.0M$210.0M$8.0M$107.0M

Latest News

Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choice Zacks · Jul 9, 2026 Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma PR Newswire · Jun 15, 2026 Inhibrx Reports First Quarter 2026 Financial Results PR Newswire · May 14, 2026 Inhibrx Biosciences (INBX) Announces Positive Interim Results From Phase 2 Portion of HexAgon Study Insider Monkey · May 14, 2026 Should Positive INBRX-106 Phase 2 Head and Neck Data Require Action From Inhibrx Biosciences (INBX) Investors? Simply Wall St. · May 12, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-80.0M$-115.0M$-193.0M$-194.0M$-130.0M
Investing Cash Flow$-2.0M$-1.0M$-9.0M$-5.0M$0
Financing Cash Flow$84.0M$129.0M$0$0$0
Net Cash Flow$3.0M$143.0M$4.0M$-125.0M$-28.0M
Free Cash Flow$-81.0M$-116.0M$-198.0M$-197.0M$-130.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.09
EV / EBITDA-9.08
FCF Yield-10.87%
Quick Ratio3.91
Interest Coverage-11.25
Return 1Y266.38%
Return 3Y—
Return 5Y—

Ownership

Insiders Held23.16%
Institutions Held82.24%
Institutions Float Held107.02%
Institutional HolderSharesReport Date
Perceptive Advisors Llc1,442,7072026-03-31
Viking Global Investors, L.P.1,437,7052026-03-31
Morgan Stanley1,263,0782026-03-31
Sanofi1,157,9262026-03-31
HighTower Advisors, LLC870,2002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Inhibrx Biosciences Inc.

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.

Inhibrx Biosciences Inc. is led by CEO Mark Paul Lappe, employs 156 people, headquartered in US, publicly traded since 2024.

Inhibrx Biosciences Inc. (INBX) stock trades at $81.54 with a market capitalization of $1.20B. The stock is valued at a price-to-earnings (P/E) ratio of -9.72, price-to-book of -60.42, price-to-sales of 920.33. Over the past 52 weeks the stock has ranged between $20.55 and $155.29, and currently trades 47.5% below its 52-week high.

On profitability, Inhibrx Biosciences Inc. generates a return on equity (ROE) of -563.89%, return on capital employed of -78.15%, an operating margin of -13500.00%, a net profit margin of -100.14%.

Official website: www.inhibrx.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides